TORONTO, Canada; HAIFA, Israel; and POMPANO BEACH, Florida, April 7, 2026
NurExone Biologic Inc. announced that its U.S. subsidiary Exo-Top has signed a strategic Letter of Intent (LOI) with BioXtek to advance GMP manufacturing, clinical supply, and commercialization of exosome-based therapies, marking a significant step in the evolution of regenerative medicine and advanced biologics production.
Strategic GMP Expansion to Accelerate Exosome Therapies
The collaboration aims to establish a robust U.S. Good Manufacturing Practice (GMP) infrastructure for the production of mesenchymal stem cell (MSC)-derived exosomes, enabling scalable and standardized supply for both clinical and commercial applications. By combining Exo-Top’s proprietary MSC Master Cell Bank (MCB) with BioXtek’s advanced manufacturing facility and cleanroom infrastructure, the partnership is expected to significantly enhance batch consistency, quality control, and manufacturing readiness.
A key objective is to ensure consistent, reproducible production of high-quality exosomes, which are increasingly recognized as a next-generation therapeutic modality. These nanoscale vesicles carry proteins, growth factors, and microRNAs, making them highly suitable for targeted drug delivery and regenerative applications.
Clinical Supply and Pipeline Advancement in Regenerative Medicine
Advertisement
A major focus of the LOI is to support clinical trial readiness and supply chain development for NurExone’s lead candidate, ExoPTEN, which targets spinal cord injury and optic nerve damage. The collaboration may enable GMP-compliant manufacturing of exosomes for U.S. clinical trials, supporting future FDA regulatory pathways and accelerated development timelines.
Additionally, the partnership will explore applications of exosomes in wound care, pain management, orthopedics, and neurological disorders, reflecting the expanding role of biologics and nanomedicine in modern healthcare. The ability to scale production while maintaining strict quality and compliance standards is critical for transitioning exosome therapies from preclinical research to clinical and commercial use.
Commercialization Potential and Global Market Impact
Beyond clinical development, the collaboration positions both companies to capitalize on the rapidly growing exosome therapeutics and regenerative aesthetics market, which is projected to exceed $1.6 billion by 2034.
BioXtek’s role as a potential U.S.-based manufacturing and distribution partner will support commercial-scale production and global market expansion, while Exo-Top will contribute technology transfer, proprietary know-how, and platform expertise. This integrated approach is expected to streamline manufacturing workflows, reduce time-to-market, and improve supply chain efficiency for advanced biologics.
Importantly, the collaboration emphasizes compliance with regulatory frameworks, including FDA requirements and international standards, ensuring that all activities meet stringent quality, safety, and validation criteria essential for cGxP environments.
Strengthening the Future of Biologics Manufacturing
This strategic LOI highlights the growing importance of GMP-compliant manufacturing platforms in the development of advanced therapies, particularly in the field of cell and exosome-based treatments. By focusing on standardization, scalability, and regulatory alignment, the partnership addresses key challenges in the biopharmaceutical manufacturing landscape.
As demand for precision medicine and regenerative therapies continues to rise, collaborations like this are expected to play a crucial role in enabling efficient production, clinical translation, and commercialization of innovative biologics.
The NurExone–BioXtek collaboration represents a significant advancement in exosome manufacturing and clinical supply infrastructure, reinforcing the role of GMP, quality systems, and scalable production technologies in shaping the future of biopharmaceutical innovation. With strong emphasis on clinical readiness, regulatory compliance, and global commercialization, this partnership is poised to accelerate the adoption of next-generation regenerative therapies.
Source: NurExone Biologic press release
